ALVR Stock Overview
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
AlloVir, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.75 |
52 Week High | US$3.13 |
52 Week Low | US$0.58 |
Beta | 0.78 |
11 Month Change | 3.16% |
3 Month Change | -2.34% |
1 Year Change | -75.11% |
33 Year Change | -96.37% |
5 Year Change | n/a |
Change since IPO | -97.03% |
Recent News & Updates
Recent updates
Here's Why AlloVir (NASDAQ:ALVR) Must Use Its Cash Wisely
Jul 13We Think AlloVir (NASDAQ:ALVR) Needs To Drive Business Growth Carefully
Feb 09Here's Why We're Watching AlloVir's (NASDAQ:ALVR) Cash Burn Situation
Oct 03Here's Why We're Watching AlloVir's (NASDAQ:ALVR) Cash Burn Situation
Jun 23Is AlloVir (NASDAQ:ALVR) In A Good Position To Deliver On Growth Plans?
Mar 02Is AlloVir (NASDAQ:ALVR) In A Good Position To Deliver On Growth Plans?
Nov 11AlloVir GAAP EPS of $0.69 beats by $1.42
Aug 04AlloVir stock surges on $126.6M securities offering
Jul 27Is AlloVir (NASDAQ:ALVR) In A Good Position To Invest In Growth?
Jul 27Here's Why We're Not Too Worried About AlloVir's (NASDAQ:ALVR) Cash Burn Situation
Mar 21AlloVir: A Comparative Study Of Its Manufacturing Process
Feb 07We're Not Very Worried About AlloVir's (NASDAQ:ALVR) Cash Burn Rate
Nov 02AlloVir, Inc.: Creating Solutions For Stem Cell Transplant Issues
Oct 02AlloVir, Inc.'s (NASDAQ:ALVR) Intrinsic Value Is Potentially 24% Below Its Share Price
Aug 06We Think AlloVir (NASDAQ:ALVR) Can Afford To Drive Business Growth
Jul 01AlloVir EPS misses by $0.08
May 06AlloVir (NASDAQ:ALVR) Is In A Good Position To Deliver On Growth Plans
Apr 01This Insider Has Just Sold Shares In AlloVir, Inc. (NASDAQ:ALVR)
Feb 07Is AlloVir, Inc.'s (NASDAQ:ALVR) Shareholder Ownership Skewed Towards Insiders?
Jan 08FDA clears AlloVir's ALVR106 application in respiratory viruses
Dec 17Allovir's COVID-19 therapy saw anti-viral activity in pre-clinical data
Dec 07We Think AlloVir (NASDAQ:ALVR) Can Afford To Drive Business Growth
Dec 04AlloVir EPS misses by $0.28
Nov 10Shareholder Returns
ALVR | US Biotechs | US Market | |
---|---|---|---|
7D | -0.8% | -1.7% | -1.4% |
1Y | -75.1% | 13.9% | 21.1% |
Return vs Industry: ALVR underperformed the US Biotechs industry which returned 13.4% over the past year.
Return vs Market: ALVR underperformed the US Market which returned 20.9% over the past year.
Price Volatility
ALVR volatility | |
---|---|
ALVR Average Weekly Movement | 7.1% |
Biotechs Industry Average Movement | 10.4% |
Market Average Movement | 6.3% |
10% most volatile stocks in US Market | 15.0% |
10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ALVR has not had significant price volatility in the past 3 months.
Volatility Over Time: ALVR's weekly volatility has decreased from 13% to 7% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2013 | 8 | Diana Brainard | www.allovir.com |
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.
AlloVir, Inc. Fundamentals Summary
ALVR fundamental statistics | |
---|---|
Market cap | US$86.73m |
Earnings (TTM) | -US$140.34m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.6x
P/E RatioIs ALVR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ALVR income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$140.34m |
Earnings | -US$140.34m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -1.23 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did ALVR perform over the long term?
See historical performance and comparison